Sign in
4

Changes in Ownership

ARROWHEAD PHARMACEUTICALS, INC. Filed Acc 0001209191-19-013821

Director sold 68,000 shares at an average $19.20 ($1,305,400)

  • Director acquired 65,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
GIVEN DOUGLAS B Director 2019-02-22 Sale −3,000 $18.05 $54,150 175,130 D: show line 1 in the form
GIVEN DOUGLAS B Director 2019-02-26 Option exercise +30,000 $5.19 $155,700 205,130 D: show line 2 in the form
GIVEN DOUGLAS B Director 2019-02-26 Option exercise +18,000 $2.19 $39,420 223,130 D: show line 3 in the form
GIVEN DOUGLAS B Director 2019-02-26 Option exercise +10,000 $2.62 $26,200 233,130 D: show line 4 in the form
GIVEN DOUGLAS B Director 2019-02-26 Option exercise +7,000 $4.75 $33,250 240,130 D: show line 5 in the form
GIVEN DOUGLAS B Director 2019-02-26 Sale −65,000 $19.25 $1,251,250 175,130 D: show line 6 in the form
Open-market sales · 68,000 sh · avg $19.20 · $1,305,400

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
GIVEN DOUGLAS B Director 2019-02-26 Option exercise · Stock Option (right to buy) −30,000 35,000 D: show line 7 in the form
GIVEN DOUGLAS B Director 2019-02-26 Option exercise · Stock Option (right to buy) −18,000 17,000 D: show line 8 in the form
GIVEN DOUGLAS B Director 2019-02-26 Option exercise · Stock Option (right to buy) −10,000 7,000 D: show line 9 in the form
GIVEN DOUGLAS B Director 2019-02-26 Option exercise · Stock Option (right to buy) −7,000 0 D: show line 10 in the form
Loading xslF345X03/doc4.xml…